Novel Genetic Variant May Drive MASLD
In an article published in Hepatology , Filippo Pinto e Vairo, MD, PhD, and colleagues described their discovery of a single inherited variant of the mesenchymal-epithelial transition ( MET ) gene in a familial case of MASLD involving a father and daughter with no apparent additional risk factors.
MASLD remains one of the world's most common diseases and will likely become the leading cause of liver cirrhosis worldwide, the researchers wrote. MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), likely stems from a combination of genetic and environmental factors, they said.
Their discovery of the gene variation prompted the researchers to investigate whether that variation and others on the MET gene were linked to steatotic liver disease.
They used Mayo Clinic's Tapestry study, a large-scale genetic sequencing project, to analyze the exome sequencing data of 3904 adults with MASLD to identify other cases and analyze them. About 1% (45 individuals) had rare variants of the MET gene potentially associated with MASLD, and 8 of the 45 (18%) had genetic variants in the same area as the index patient and her father.
Pinto e Vairo, medical director of the Program for Rare and Undiagnosed Diseases in the Mayo Clinic's Center for Individualized Medicine, explained the potential implications of the findings in a Q&A with Medscape Medical News .
What prompted you to conduct this research? How did you identify the original patient?
Pinto e Vairo: The original patient was identified through clinical care and underwent liver biopsy due to elevated liver enzymes. Her histology confirmed MASH [metabolic dysfunction–associated steatohepatitis], and subsequent exome sequencing revealed a novel heterozygous MET variant, inherited from her affected father, which led to a deeper investigation into the genetic basis of her condition.
Were you surprised by any of the findings? Why or why not?
Pinto e Vairo: The findings were surprising in several ways. First, variants in MET had not previously been implicated as a germline monogenic cause of MASLD or MASH in humans. Its known roles had largely been confined to cancer. Second, the discovery that rare, loss-of-function variants in the MET kinase domain could underlie liver steatosis and inflammation ran counter to the usual oncogenic MET variants, which are typically gain-of-function.
The confirmation that the MET variants impaired downstream signaling further reinforced a novel mechanism. The lack of high polygenic risk scores in patients with these MET variants also highlighted that monogenic drivers might be underrecognized contributors to MASLD/MASH.
Based on your research and other research, how might genetics play into MASLD?
Pinto e Vairo: Genetics play a significant role in MASLD by modulating both susceptibility and disease progression. While large-scale genome-wide association studies have identified common variants — such as those in PNPLA3 , TM6SF2 , GCKR , MBOAT7 , and HSD17B13 — that confer risk or protection, this study adds evidence that rare monogenic variants can also independently drive the disease.
This suggests a genetic spectrum in MASLD, ranging from polygenic, environmentally modulated forms to monogenic cases with high penetrance. The interplay between these rare variants and broader metabolic context will be crucial to understand personalized risk.
Is there a practical application for this research now? What might the future clinical applications be?
Pinto e Vairo: The immediate practical application lies in the potential for early identification of individuals at high risk for MASLD/MASH through exome or genome sequencing, particularly in families with a strong history of liver disease. Clinically, this could justify enhanced surveillance or earlier lifestyle and therapeutic interventions in at-risk individuals.
In the future, this research may support the development of targeted therapies that can restore or bypass defective MET signaling. Moreover, it opens the door to personalized medicine strategies that consider a patient's unique genetic profile when choosing interventions or preventive strategies.
What are the next steps?
Pinto e Vairo: The next steps include functional validation of other rare MET variants to better understand their pathogenic potential and variability in phenotypic expression; longitudinal cohort studies to monitor disease progression in individuals with MET variants and to define genotype-phenotype correlations more precisely; and ultimately therapeutic exploration, including in vitro and in vivo modeling, to determine whether restoring MET signaling could reverse or mitigate disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
16 minutes ago
- Fast Company
Wegovy and Zepbound patients are resorting to these cost-saving measures to stay on the weight-loss drugs
Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but as more U.S. insurers restrict coverage people are trimming costs by stretching doses or forgoing expenditures like vacations to pay for the medication out of pocket. A half dozen doctors who spoke with Reuters said insurance coverage has tightened in 2025 as many employers drop it for the expensive GLP-1 drugs. While patients on these medications are counseled on proper diet and exercise, clinical trials show that people who stop taking these drugs are apt to regain weight. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are weekly injections with U.S. insurer list prices of more than $1,000 a month. For customers willing to pay cash, both drugmakers will ship directly for $499 a month if refills are purchased at fixed intervals. 'A significant number of my patients now pay cash,' said Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine in Chicago. 'People find a way to scrounge up $6,000 a year, which sucks, because that's a vacation or two.' Subscribe to the Daily newsletter. Fast Company's trending stories delivered to you every day Privacy Policy | Fast Company Newsletters More than a billion people worldwide are obese, according to the U.N. World Health Organization, which has said the GLP-1 drugs could help end the obesity pandemic. 'A KIND OF PURGATORY' A tech industry job change for Yelena Kibasova, a 40-year-old who lives in the Minneapolis area, meant loss of coverage for her Zepbound prescription that helped her achieve and maintain a 150-pound (68-kg) weight loss. GLP-1 patient Yelena Kibasova, 40, poses in this undated handout picture. [Photo: @morethanmyweight/Handout via Reuters] 'My new company does not cover GLP-1s, so now I am in a kind of purgatory,' Kibasova said. 'I stopped doing my nails. I stopped doing my hair. Those things are not as important as me staying at a healthy weight.' The doctors interviewed by Reuters said patients once leery about long-term obesity treatment are now more comfortable staying on a drug. The doctors said that conversations about temporary use happen only when a patient is trying to lose a certain amount of weight for issues such as fertility treatment or an organ transplant. These obesity specialists said they are hopeful that competition will help bring down prices as new weight-loss options emerge, including new oral drugs that may be available next year. Lilly last week announced trial results for its easier-to-manufacture pill, which was shown to cut patient weight by 12.4%, a few percentage points less than injected drugs. The company hopes to launch it in August 2026. Kenneth Custer, Lilly's head of cardiometabolic health, told Reuters the pill is being tested in several settings, including as a maintenance therapy. Custer declined to comment on how it might be priced. MEDICATION FOR MAINTENANCE Dr. Anne Peters, an endocrinologist at Keck Medicine USC in Los Angeles, said it is important that patients who reach their weight-loss goal not stop a prescription 'cold turkey,' so the dose can be tapered down over several months. Peters said about a third of her patients are able to reduce their dose and maintain weight loss, while the rest need to stay on the medication. An analysis of U.S. pharmacy insurance claims found that nearly two-thirds of patients who started on Wegovy or Zepbound in 2024 were still on the medications a year later. advertisement Peters said she uses 'every technique in the book' to secure insurance coverage for patients, but noted that a growing number of plans no longer pay for the treatments, and patients have to pay out-of-pocket. U.S. pharmacies supply self-injection pens pre-loaded with doses of Wegovy or Zepbound. Lilly's direct-to-consumer service also offers vials. 'Some patients can stretch out the vials longer. Get 15 mg, and then give a 10 mg dose for instance,' Dr. Peters said, noting that the drug's instructions advise that such an approach should not be taken. Doses of 5 mg, 10 mg and 15 mg are recommended for weight-loss maintenance. Patients also are turning to lower-cost compounded versions of the GLP-1 drugs, or are even mixing them at home with raw ingredients, both of which Peters and other doctors advise against due to safety concerns. Dr. Angela Fitch, former president of the Centennial, Colorado-based Obesity Medicine Association and chief medical officer at online primary care provider Knownwell, said nobody wants to be on a medication, but patients who respond to a GLP-1 drug 'really don't want to go off of it when they recognize that it has such a value to them.' Both Wegovy and Zepbound were first launched, under the brand names Ozempic and Mounjaro, as diabetes treatments. The class has been linked to a range of benefits, including improved heart health and less sleep apnea. Fitch said the most common reason for her patients to stop taking a GLP-1 drug is loss of insurance coverage. She said her experience is that about 10% of patients are able to reach a target weight and maintain it without further treatment. 'We are in a dip where people are dropping coverage,' Fitch said, adding that the direct-to-consumer options are an 'upper-ish middle-class thing.' —Deena Beasley, Reuters
Medscape
16 minutes ago
- Medscape
Optimizing Therapies for HR+ Early-Stage Breast Cancer
Hormone receptor-positive (HR+) early-stage breast cancer is one of the most common types of breast cancer, characterized by tumor cells that have receptors for estrogen or progesterone hormones. Although significant progress has been made in screening, treatment, and surgery, the risk of recurrence still remains. To explore therapies for managing HR+ early-stage breast cancer, Medscape spoke with Hope S. Rugo, MD, FASCO, division chief of breast medical oncology and a professor of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Center, Duarte, California, and professor emeritus at the University of California San Francisco. Read on for her insights. What role does risk stratification play in determining therapy for HR+ early-stage breast cancer? Hope S. Rugo, MD, FASCO This is a critical area. It is a key aspect of determining appropriate treatment and extent of treatment, and we are still learning more about how to appropriately stratify based on clinicopathologic and genomic characteristics. Gene expression tests are used widely to understand prognosis and benefit from chemotherapy, but there are ongoing issues in HR+ disease including disease heterogeneity and how to optimally treat very young women with HR+ disease. We use clinicopathologic data in combination with gene expression tests to stratify risk, but this approach doesn't always provide us with the necessary information for determining the optimal adjuvant or neoadjuvant treatment. The adjuvant CDK4/6 inhibitor trials will be helpful, as they will allow for longer follow-up of patients with high- and intermediate-risk disease. Additionally, newer predictors, such as gene expression signatures that may estimate the benefit from immunotherapy, are also being evaluated. What factors influence your choice between endocrine therapy and chemotherapy for HR+ early-stage breast cancer? Multiple factors have an influence on the choice of therapy, including the extent of disease and tumor biology. We have also learned that the intensity or extent of estrogen positivity plays a role in endocrine sensitivity. In terms of tumor biology, understanding tumor proliferation and chemotherapy sensitivity is critical. We are currently using gene expression tests, but it is clear that these are insufficient, even within the context of age and tumor burden. Additional markers that help to identify up-front or emerging resistance to endocrine therapy are critical. Data from the CDK4/6 inhibitor adjuvant trials has further complicated this question — as now the issue is where optimal outcome can be achieved in less chemotherapy-responsive, higher-risk disease with the addition of abemaciclib or ribociclib. Considering recent research, is extended endocrine therapy actually beneficial? I believe it is, but careful consideration needs to be given to the decision to extend therapy. Disease burden is of course our first consideration, but sensitivity to endocrine therapy, development of resistance, and response to chemotherapy in appropriate cases need to be taken into consideration. Interestingly, several analyses have suggested that patients with low proliferative and genomic risk, but a higher disease burden, might be most likely to benefit from extended duration endocrine therapy due to the long natural history of this disease. We are now exploring the use of switching the type of endocrine therapy in the high-risk adjuvant setting and the use of circulating tumor DNA (ctDNA) to optimize therapy. What role do CDK4/6 inhibitors play in the adjuvant setting for HR+ early-stage disease? Both abemaciclib and ribociclib have reduced the risk of recurrence and the risk of distant recurrence in patients with intermediate or high-risk early-stage breast cancer. The duration of therapy varies, and eligibility criteria overlap; however, the recent NATALEE trial included a diverse population, including an intermediate-risk group (stage II, node-negative with additional risk factors) to evaluate the role of the CDK4/6 inhibitors among such populations. The striking aspect of this trial was the carry-over effect, shown most clearly in the monarchE study with 5-year follow-up. Even 3 years after completing treatment with abemaciclib, the data showed an increasing impact on disease-free survival and distant disease-free survival. Although there has been no overall survival impact yet, fewer patients with abemaciclib in monarchE are living with metastatic disease. What are the most critical research gaps or upcoming trials that could reshape how we manage HR+ early-stage breast cancer in the upcoming years? A few main things to address are improving risk stratification, how to use ctDNA to improve outcome, and understanding if use of oral selective estrogen receptor degrader (SERDs) in sequence improve outcome and their optimal therapy duration. So far, studies using ctDNA to assess risk and guide therapy changes have been challenging due to the low number of positive ctDNA results. Moreover, ctDNA detection has sometimes coincided with metastatic disease already visible on scans in case of several aggressive cancers. We still don't know the optimal treatment approach when molecular evidence of disease is found, which is making studies focus on adding targeted therapy or changing endocrine therapy. Several trials are evaluating oral SERDs in the early stage setting for the treatment of high-risk disease. While these trials will also collect ctDNA, patient eligibility is not based on these tests. One very important area that requires additional research is understanding early-stage breast cancer in young women, where tumors seem to behave poorly — particularly in women under the age of 40 — even when patients are treated with optimal therapy. Understanding optimal therapy is a key research focus, and further investigation of biological drivers in both ductal and lobular cancers is warranted. The OFFSET trial aims to determine the value of adjuvant chemotherapy vs ovarian function suppression in conjunction with standard endocrine therapy and CDK4/6 inhibitors as indicated. However, this study is challenging to enroll in. Hope S. Rugo, MD, FASCO, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Chugai; Puma; Sanofi; Napo; Mylan Received research grant from: AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Stemline Therapeutics; OBI Pharma; Ambrx
Fox News
18 minutes ago
- Fox News
Cowboys' Jerry Jones reveals scary skin cancer battle
Dallas Cowboys team owner Jerry Jones revealed he overcame an off-the-field battle as he holds out hope that the organization he helped make one of the most valuable in sports reaches the Super Bowl once more. Jones revealed in an interview with the Dallas Morning News that he was diagnosed with stage 4 melanoma skin cancer in June 2010 and started his treatment soon after. The report noted that Jones slightly touched on undergoing cancer treatments a "dozen years ago" during one of the episodes of the Netflix docuseries "America's Team: The Gambler and His Cowboys." "I was saved by a fabulous treatment and great doctors and a real miracle (drug) called PD-1 (therapy)," he told the Morning News. "I went into trials for that PD-1 and it has been one of the great medicines. "I now have no tumors." Jones said he's had four surgeries over the last 10 years – two on his lungs and two to deal with his lymph nodes. Melanoma is a less common form of skin cancer that is more dangerous than other varieties because it's much more likely to spread to other parts of the body if not found and treated early, according to the American Cancer Society. The Melanoma Research Alliance said stage 4 means the cancer "metastasized (spread) to other places throughout the body, such as the brain, lungs, liver, or gastrointestinal (GI) tract." "The 5-year survival rate as of 2018 for distant metastatic (Stage IV) melanoma is 22.5%," the research organization stated on its website. Jones, 82, is set to embark on another NFL season as the head of the Cowboys. Sportico revealed its NFL valuations on Wednesday with the Cowboys leading the league at $12.8 billion.
